KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quest Diagnostics (DGX) Cash from Investing Activities (2016 - 2025)

Quest Diagnostics' Cash from Investing Activities history spans 17 years, with the latest figure at -$191.0 million for Q4 2025.

  • For Q4 2025, Cash from Investing Activities rose 61.95% year-over-year to -$191.0 million; the TTM value through Dec 2025 reached -$631.0 million, up 75.24%, while the annual FY2025 figure was -$631.0 million, 75.24% up from the prior year.
  • Cash from Investing Activities for Q4 2025 was -$191.0 million at Quest Diagnostics, up from -$201.0 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $437.0 million in Q2 2021 and bottomed at -$1.6 billion in Q3 2024.
  • The 5-year median for Cash from Investing Activities is -$163.5 million (2022), against an average of -$238.1 million.
  • The largest annual shift saw Cash from Investing Activities soared 313.17% in 2021 before it tumbled 1426.17% in 2024.
  • A 5-year view of Cash from Investing Activities shows it stood at -$227.0 million in 2021, then grew by 23.35% to -$174.0 million in 2022, then surged by 34.48% to -$114.0 million in 2023, then plummeted by 340.35% to -$502.0 million in 2024, then soared by 61.95% to -$191.0 million in 2025.
  • Per Business Quant, the three most recent readings for DGX's Cash from Investing Activities are -$191.0 million (Q4 2025), -$201.0 million (Q3 2025), and -$124.0 million (Q2 2025).